Mercury Biopharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Mercury Biopharmaceutical has a total shareholder equity of NT$388.4M and total debt of NT$41.6M, which brings its debt-to-equity ratio to 10.7%. Its total assets and total liabilities are NT$438.1M and NT$49.7M respectively.
Key information
10.7%
Debt to equity ratio
NT$41.60m
Debt
Interest coverage ratio | n/a |
Cash | NT$329.07m |
Equity | NT$388.35m |
Total liabilities | NT$49.72m |
Total assets | NT$438.08m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6932's short term assets (NT$339.9M) exceed its short term liabilities (NT$8.1M).
Long Term Liabilities: 6932's short term assets (NT$339.9M) exceed its long term liabilities (NT$41.7M).
Debt to Equity History and Analysis
Debt Level: 6932 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 6932's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6932 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6932 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 56.5% each year